75N95022Q00268

Submitted by pluggern on Mon, 06/13/2022 - 13:59
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
Analysis of accessible chromatin regions during induced pluripotent stem cell (iPSC) cell culture
Contracting Office
National Institute on Drug Abuse (NIDA)

Contact Points

Primary Contract Specialist

Bryan
Lewis
bryan.lewis@nih.gov

Secondary Contracting Officer

Rieka
Plugge
rieka.plugge@nih.gov
NAICS Code Number
541380
The ATAC-seq identifies accessible DNA regions by probing open chromatin with hyperactive mutant Tn5 transposase that inserts sequencing adapters into open regions of the genome. The mutant Tn5 transposase excises any sufficiently long DNA in a process called tagmentation: the simultaneous fragmentation and tagging of DNA performed by Tn5 transposase pre-loaded with sequencing adaptors. The tagged DNA fragments are then purified, amplified by PCR and sent for sequencing. Sequencing reads can then be used to infer regions of increased accessibility as well as to map regions of transcription-factor binding sites and nucleosome positions. The key element of the ATAC-seq procedure is the action of the transposase Tn5 on the genomic DNA of the sample. Transposases are enzymes catalyzing the movement of transposons to other parts in the genome (5). While naturally occurring transposases have a low level of activity, ATAC-seq employs a mutated hyperactive transposase.
Small Business Size Standard
$16.5 million
FPDS Classification Code
6505
Estimated Period of Performance
The anticipated period of performance is 2-months from the effective date of award.
Set-Aside Status
Not Set Aside
Competition Status
Competitive
Background/Description of Requirement

The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives.
The NCATS is a part of the National Institutes of Health (NIH), with the mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The SCTL is a state-of-the-art research facility within NCATS’ Division of Pre-Clinical Innovation dedicated to addressing the scientific and technological challenges in the iPSC field. The SCTL uses an integrated technological approach to better understand pluripotent stem cell biology and thereby leverage drug discovery and regenerative medicine.
The SCTL aims to develop novel cell culture conditions that reduce genomic instability and increase the safety of iPSC technologies. The ATAC-Seq services required are an integral part of the suite of analysis methods that NCATS will carry out to construct a high-resolution “map” of the genomic and epigenomic landscape that controls human pluripotency. The integration of all these analyses will allow NCATS to generate foundational cell culture methods that will be shared with the scientific community.

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.